Core Insights - Nexalin Technology, Inc. has received a U.S. Design Patent for its HALO™ Clarity neuromodulation device, providing 15 years of design protection, which enhances its intellectual property portfolio [1][5] Group 1: Product Overview - HALO™ Clarity is a non-invasive neuromodulation device aimed at treating mental health and neurological conditions, including Alzheimer's, without the need for pharmaceuticals or surgery [2][3] - The device is designed for at-home use under professional supervision, allowing remote monitoring and guidance from physicians, which can improve patient access and reduce healthcare costs [3][8] Group 2: Clinical Development - Nexalin is conducting multiple clinical studies for HALO™ Clarity targeting conditions such as anxiety, insomnia, PTSD, and mild traumatic brain injury, with positive feedback from the FDA on pivotal trial designs [4] - The DIFS™ platform has been involved in over two dozen trials globally, showing consistent safety and efficacy signals [4] Group 3: Advantages of HALO™ Clarity - The device offers enhanced convenience by allowing therapy at home, reducing the need for frequent office visits [8] - It enables remote clinician oversight, allowing real-time data review and protocol adjustments through telemedicine [8] - The system may improve treatment compliance and continuity while potentially lowering overall care costs by minimizing in-clinic resource requirements [8]